Fig. 7: ACT benefits based on DFS according to pN stage and PS. | npj Precision Oncology

Fig. 7: ACT benefits based on DFS according to pN stage and PS.

From: High-throughput proteomics profiling-derived signature associated with chemotherapy response and survival for stage II/III colorectal cancer

Fig. 7

a–c Kaplan-Meier DFS curves are shown for patients according to their use of ACT. In addition, patients with a high PS (left) were stratified according to pN0 (n = 206, upper), pN1 (n = 154, middle), and pN2 (n = 76, bottom). Patients with a low PS (right) were also stratified according to pN0 (n = 118, upper), pN1 (n = 75, middle), and pN2 (n = 23, bottom). p values were calculated using two-sided log-rank test. PS Proteomic signature, DFS Disease-free survival, HR Hazard ratio, CI Confidential interval.

Back to article page